Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures

Wayne D. Hsueh, Peter H. Hwang, Waleed M. Abuzeid

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective The perioperative management of patients undergoing otolaryngologic procedures is increasingly complicated by the use of newer antithrombotic agents. Furthermore, with advances in anesthesia and surgical technique, otolaryngologists are presented with the challenge of operating on patients with advanced comorbid diseases. The objective of this review is to provide evidence-based recommendations on perioperative antithrombotic management for common otolaryngologic procedures. Data Sources PubMed/MEDLINE. Review Methods Selected literature on patient-specific thromboembolic risk, rate of bleeding complications in otolaryngologic procedures, and the interruption of antithrombotic therapy is reviewed and interpreted by expert opinion. Conclusions By stratifying patients into either low thromboembolic risk (‰5%) or high thromboembolic risk (>5%) and interpreting this in the context of procedural bleed risk and potential clinical consequences in the event of a bleed, otolaryngologists can make evidence-based decisions to determine the appropriate perioperative management of antithrombotic therapy. Implications for Practice When the perioperative management of antithrombotic therapy is being decided, 3 critical factors must be considered systematically: the patient;euro™s inherent thromboembolic risk, the risk and potential consequences of bleeding related to the procedure, and the timing of interruption of thromboembolic therapy.

Original languageEnglish (US)
Pages (from-to)493-503
Number of pages11
JournalOtolaryngology - Head and Neck Surgery (United States)
Volume153
Issue number4
DOIs
StatePublished - Oct 1 2015

Fingerprint

Therapeutics
Hemorrhage
Fibrinolytic Agents
Information Storage and Retrieval
Expert Testimony
PubMed
MEDLINE
Anesthesia
Otolaryngologists

Keywords

  • anticoagulation
  • antithrombotics
  • perioperative management

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery
  • Medicine(all)

Cite this

Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures. / Hsueh, Wayne D.; Hwang, Peter H.; Abuzeid, Waleed M.

In: Otolaryngology - Head and Neck Surgery (United States), Vol. 153, No. 4, 01.10.2015, p. 493-503.

Research output: Contribution to journalArticle

@article{39002520574f46c2b6d7c617c19ee2d5,
title = "Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures",
abstract = "Objective The perioperative management of patients undergoing otolaryngologic procedures is increasingly complicated by the use of newer antithrombotic agents. Furthermore, with advances in anesthesia and surgical technique, otolaryngologists are presented with the challenge of operating on patients with advanced comorbid diseases. The objective of this review is to provide evidence-based recommendations on perioperative antithrombotic management for common otolaryngologic procedures. Data Sources PubMed/MEDLINE. Review Methods Selected literature on patient-specific thromboembolic risk, rate of bleeding complications in otolaryngologic procedures, and the interruption of antithrombotic therapy is reviewed and interpreted by expert opinion. Conclusions By stratifying patients into either low thromboembolic risk (‰5{\%}) or high thromboembolic risk (>5{\%}) and interpreting this in the context of procedural bleed risk and potential clinical consequences in the event of a bleed, otolaryngologists can make evidence-based decisions to determine the appropriate perioperative management of antithrombotic therapy. Implications for Practice When the perioperative management of antithrombotic therapy is being decided, 3 critical factors must be considered systematically: the patient;euro™s inherent thromboembolic risk, the risk and potential consequences of bleeding related to the procedure, and the timing of interruption of thromboembolic therapy.",
keywords = "anticoagulation, antithrombotics, perioperative management",
author = "Hsueh, {Wayne D.} and Hwang, {Peter H.} and Abuzeid, {Waleed M.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1177/0194599815600409",
language = "English (US)",
volume = "153",
pages = "493--503",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures

AU - Hsueh, Wayne D.

AU - Hwang, Peter H.

AU - Abuzeid, Waleed M.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objective The perioperative management of patients undergoing otolaryngologic procedures is increasingly complicated by the use of newer antithrombotic agents. Furthermore, with advances in anesthesia and surgical technique, otolaryngologists are presented with the challenge of operating on patients with advanced comorbid diseases. The objective of this review is to provide evidence-based recommendations on perioperative antithrombotic management for common otolaryngologic procedures. Data Sources PubMed/MEDLINE. Review Methods Selected literature on patient-specific thromboembolic risk, rate of bleeding complications in otolaryngologic procedures, and the interruption of antithrombotic therapy is reviewed and interpreted by expert opinion. Conclusions By stratifying patients into either low thromboembolic risk (‰5%) or high thromboembolic risk (>5%) and interpreting this in the context of procedural bleed risk and potential clinical consequences in the event of a bleed, otolaryngologists can make evidence-based decisions to determine the appropriate perioperative management of antithrombotic therapy. Implications for Practice When the perioperative management of antithrombotic therapy is being decided, 3 critical factors must be considered systematically: the patient;euro™s inherent thromboembolic risk, the risk and potential consequences of bleeding related to the procedure, and the timing of interruption of thromboembolic therapy.

AB - Objective The perioperative management of patients undergoing otolaryngologic procedures is increasingly complicated by the use of newer antithrombotic agents. Furthermore, with advances in anesthesia and surgical technique, otolaryngologists are presented with the challenge of operating on patients with advanced comorbid diseases. The objective of this review is to provide evidence-based recommendations on perioperative antithrombotic management for common otolaryngologic procedures. Data Sources PubMed/MEDLINE. Review Methods Selected literature on patient-specific thromboembolic risk, rate of bleeding complications in otolaryngologic procedures, and the interruption of antithrombotic therapy is reviewed and interpreted by expert opinion. Conclusions By stratifying patients into either low thromboembolic risk (‰5%) or high thromboembolic risk (>5%) and interpreting this in the context of procedural bleed risk and potential clinical consequences in the event of a bleed, otolaryngologists can make evidence-based decisions to determine the appropriate perioperative management of antithrombotic therapy. Implications for Practice When the perioperative management of antithrombotic therapy is being decided, 3 critical factors must be considered systematically: the patient;euro™s inherent thromboembolic risk, the risk and potential consequences of bleeding related to the procedure, and the timing of interruption of thromboembolic therapy.

KW - anticoagulation

KW - antithrombotics

KW - perioperative management

UR - http://www.scopus.com/inward/record.url?scp=84943158238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943158238&partnerID=8YFLogxK

U2 - 10.1177/0194599815600409

DO - 10.1177/0194599815600409

M3 - Article

C2 - 26307580

AN - SCOPUS:84943158238

VL - 153

SP - 493

EP - 503

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 4

ER -